Current Diabetes Reports

, 18:75 | Cite as

Inpatient Glycemic Management in the Setting of Renal Insufficiency/Failure/Dialysis

  • Ravi Iyengar
  • Jennifer Franzese
  • Roma GianchandaniEmail author
Hospital Management of Diabetes (A Wallia and JJ Seley, Section Editors)
Part of the following topical collections:
  1. Topical Collection on Hospital Management of Diabetes


Purpose of this Review

Chronic diabetic nephropathy and renal dysfunction from other causes are common in hospitalized patients with diabetes. Available diabetes management guidelines aim to reduce hyperglycemia and hypoglycemia, both independent risk factors for hospital outcomes. Renal dysfunction, which increases the risk of hypoglycemia, adds a layer of complexity in diabetes management. Therefore, modified glucose goals and treatment regimens may be required.

Recent Findings

Recent prospective and retrospective studies provide direction on safe insulin therapy for diabetes inpatients with renal compromise. Studies of newer diabetes pharmacotherapy provide data on oral agent use in the inpatient setting.


Diabetes therapy should be modified with changing renal function. Glucose management in patients on peritoneal or hemodialysis is challenging. Reducing weight-based doses of insulin and use of newer insulins can reduce hypoglycemia risk. Safety and efficacy of DPP-4 inhibitors has been evaluated in the hospital and nursing home setting. Metformin, SGLT-2 inhibitors, and GLP1 receptor agonists can be used in several stages of renal dysfunction prior to and at discharge.


Inpatient diabetes Insulin management End-stage renal disease Hemodialysis Peritoneal Dialysis Antidiabetic agents 


Compliance with Ethical Standards

Conflict of Interest

Ravi Iyengar, Jennifer Franzese, and Roma Gianchandani declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Aldukhayel A. Prevalence of diabetic nephropathy among type 2 diabetic patients in some of the Arab countries. Int J Health Sci (Qassim). 2017;11(1):1–4.Google Scholar
  2. 2.
    Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein-Fuchs J, et al. Diabetic kidney disease: a report from an ADA consensus conference. Diabetes Care. 2014;37(10):2864–83.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Thakar CV, Christianson A, Himmelfarb J, Leonard AC. Acute kidney injury episodes and chronic kidney disease risk in diabetes mellitus. Clin J Am Soc Nephrol. 2011; Scholar
  4. 4.
    Umpierrez GE, Hellman R, Korytkowski MT, Kosiborod M, Maynard GA, Montori VM, et al. Management of hyperglycemia in hospitalized patients in non-critical care setting: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2012;97(1):16–38.CrossRefPubMedGoogle Scholar
  5. 5.
    Moghissi ES, Korytkowski MT, DiNardo M, Einhorn D, Hellman R, Hirsch IB, et al. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Endocr Pract. 2009;15(4):353–69.CrossRefPubMedGoogle Scholar
  6. 6.
    • Hung AM, Siew ED, Wilson OD, Perkins AM, Greevy RA, Horner J, et al. Risk of hypoglycemia following hospital discharge in patients with diabetes and acute kidney injury. Diabetes Care. 2018;41(3):503–12. Important recognition on the risk of hypoglycemic post-discharge in patients with compromised renal function. CrossRefPubMedGoogle Scholar
  7. 7.
    Bakris GL, Molitch M. Are all patients with type 1 diabetes destined for dialysis if they live long enough? Probably Not. Diabetes Care. 2018;41(3):389–90.CrossRefPubMedGoogle Scholar
  8. 8.
    • Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28. The EMPA-REG trial demonstrates cardiovascular benefits in patients with diabetes on empagliflozin, which has significantly increased the improtance and use of SGLT-2 inhibitors in many diabetes regimens. CrossRefGoogle Scholar
  9. 9.
    • Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22. The LEADER trial similarly demonstrated improved cardiovascular benefits in patients on liraglutide, increasing the utility of GLP-1 agonists in diabetes regimens. CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Mak R. Renal disease, insulin resistance, and glucose intolerance. Diabetes Rev. 1994;2(1):19–28.Google Scholar
  11. 11.
    Dzurik R, Spustova V, Lajdova I. Inhibition of glucose utilization in isolated rat soleus muscle by pseudouridine: implications for renal failure. Nephron. 1993;65(1):108–10.CrossRefPubMedGoogle Scholar
  12. 12.
    Mak RH. 1, 25-dihydroxyvitamin D3 corrects insulin and lipid abnormalities in uremia. Kidney Int. 1998;53(5):1353–7.CrossRefPubMedGoogle Scholar
  13. 13.
    Mak R, Bettinelli A, Turner C, Haycock GB, Chantler C. The influence of hyperparathyroidism on glucose metabolism in uremia. J Clin Endocrinol Metab. 1985;60(2):229–33.CrossRefPubMedGoogle Scholar
  14. 14.
    Mak R, Turner C, Haycock G, Chantler C. Secondary hyperparathyroidism and glucose intolerance in children with uremia. Kidney Int Suppl. 1983;16:S128–33.PubMedGoogle Scholar
  15. 15.
    Guthoff M, Wagner R, Vosseler D, Peter A, Nadalin S, Häring H-U, et al. Impact of end-stage renal disease on glucose metabolism—a matched cohort analysis. Nephrol Dial Transplant. 2017;32(4):670–6.CrossRefPubMedGoogle Scholar
  16. 16.
    • Gianchandani RY, Neupane S, Heung M. Hypoglycemia in hospitalized hemodialysis patients with diabetes: an observational study. J Diabetes Sci Technol. 2018;12(1):33–8. This study is one of first to highlight the important relationship of hypoglycemia in hospitalized patients on dialysis. CrossRefPubMedGoogle Scholar
  17. 17.
    Association AD. 6. Glycemic targets: standards of medical care in diabetes—2018. Diabetes Care. 2018;41(Supplement 1):S55–64.CrossRefGoogle Scholar
  18. 18.
    Shurraw S, Hemmelgarn B, Lin M, Majumdar SR, Klarenbach S, Manns B, et al. Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: a population-based cohort study. Arch Intern Med. 2011;171(21):1920–7.CrossRefPubMedGoogle Scholar
  19. 19.
    Kalantar-Zadeh K, Kopple JD, Regidor DL, Jing J, Shinaberger CS, Aronovitz J, et al. A1C and survival in maintenance hemodialysis patients. Diabetes Care. 2007;30(5):1049–55.CrossRefPubMedGoogle Scholar
  20. 20.
    Draznin B. Managing diabetes and hyperglycemia in the hospital setting: a clinician’s guide: American Diabetes Association; 2016.Google Scholar
  21. 21.
    Kovesdy CP, Park JC, Kalantar-Zadeh K, editors. Glycemic control and burnt-out diabetes in ESRD. Seminars in dialysis; 2010: Wiley Online Library.Google Scholar
  22. 22.
    Flückiger R, Harmon W, Meier W, Loo S, Gabbay KH. Hemoglobin carbamylation in uremia. N Engl J Med. 1981;304(14):823–7.CrossRefPubMedGoogle Scholar
  23. 23.
    Tonyushkina K, Nichols JH. Glucose meters: a review of technical challenges to obtaining accurate results. Journal of diabetes science and technology. 2009;3(4):971–80.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Perera N, Stewart P, Williams P, Chua E, Yue D, Twigg S. The danger of using inappropriate point-of-care glucose meters in patients on icodextrin dialysis. Diabet Med. 2011;28(10):1272–6.CrossRefPubMedGoogle Scholar
  25. 25.
    Sbrignadello S, Pacini G, Tura A. Determination of glucose levels during dialysis treatment: different sensors and technologies. J Sens. 2016;2016:1–8.CrossRefGoogle Scholar
  26. 26.
    Guillausseau P, Charles M, Godard V, Timsit J, Chanson P, Paolaggi F, et al. Comparison of fructosamine with glycated hemoglobin as an index of glycemic control in diabetic patients. Diabetes Res (Edinb, Scotl). 1990;13(3):127–31.Google Scholar
  27. 27.
    Johnson RN, Metcalf PA, Baker JR. Fructosamine: a new approach to the estimation of serum glycosylprotein. An index of diabetic control. Clin Chim Acta. 1983;127(1):87–95.CrossRefPubMedGoogle Scholar
  28. 28.
    Armbruster DA. Fructosamine: structure, analysis, and clinical usefulness. Clin Chem. 1987;33(12):2153–63.PubMedGoogle Scholar
  29. 29.
    Koga M, Kasayama S. Clinical impact of glycated albumin as another glycemic control marker. Endocr J. 2010;57(9):751–62.CrossRefPubMedGoogle Scholar
  30. 30.
    Ansari A, Thomas S, Goldsmith D. Assessing glycemic control in patients with diabetes and end-stage renal failure. Am J Kidney Dis. 2003;41(3):523–31.CrossRefPubMedGoogle Scholar
  31. 31.
    Inaba M, Okuno S, Kumeda Y, Yamada S, Imanishi Y, Tabata T, et al. Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection. J Am Soc Nephrol. 2007;18(3):896–903.CrossRefPubMedGoogle Scholar
  32. 32.
    Peacock T, Shihabi Z, Bleyer A, Dolbare E, Byers J, Knovich M, et al. Comparison of glycated albumin and hemoglobin A1c levels in diabetic subjects on hemodialysis. Kidney Int. 2008;73(9):1062–8.CrossRefPubMedGoogle Scholar
  33. 33.
    Okada T, Nakao T, Matsumoto H, Shino T, Nagaoka Y, Tomaru R, et al. Association between markers of glycemic control, cardiovascular complications and survival in type 2 diabetic patients with end-stage renal disease. Intern Med. 2007;46(12):807–14.CrossRefPubMedGoogle Scholar
  34. 34.
    Fukuoka K, Nakao K, Morimoto H, Nakao A, Takatori Y, Arimoto K, et al. Glycated albumin levels predict long-term survival in diabetic patients undergoing haemodialysis. Nephrology. 2008;13(4):278–83.CrossRefPubMedGoogle Scholar
  35. 35.
    Charpentier G, Riveline J, Varroud-Vial M. Management of drugs affecting blood glucose in diabetic patients with renal failure. Management. 2011;110897Google Scholar
  36. 36.
    Dobri GA, Lansang MC. Q: how should we manage insulin therapy before surgery? Cleve Clin J Med. 2013;80(11):702–4.CrossRefPubMedGoogle Scholar
  37. 37.
    Rosenblatt SI, Dukatz T, Jahn R, Ramsdell C, Sakharova A, Henry M, et al. Insulin glargine dosing before next-day surgery: comparing three strategies. J Clin Anesth. 2012;24(8):610–7.CrossRefPubMedGoogle Scholar
  38. 38.
    Baldwin D, Zander J, Munoz C, Raghu P, DeLange-Hudec S, Lee H, et al. A randomized trial of two weight-based doses of insulin glargine and glulisine in hospitalized subjects with type 2 diabetes and renal insufficiency. Diabetes Care. 2012;35(10):1970–4.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Kulozik F, Hasslacher C. Insulin requirements in patients with diabetes and declining kidney function: differences between insulin analogues and human insulin? Ther Adv Endocrinol Metab. 2013;4(4):113–21.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Khanna R. Dialysis considerations for diabetic patients. Kidney Int Suppl. 1993;40:S58.PubMedGoogle Scholar
  41. 41.
    Sobngwi E, Enoru S, Ashuntantang G, Azabji-Kenfack M, Dehayem M, Onana A, et al. Day-to-day variation of insulin requirements of patients with type 2 diabetes and end-stage renal disease undergoing maintenance hemodialysis. Diabetes Care. 2010;33(7):1409–12.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Aisenpreis U, Pfützner A, Giehl M, Keller F, Jehle P. Pharmacokinetics and pharmacodynamics of insulin lispro compared with regular insulin in haemodialysis patients with diabetes mellitus. Nephrol Dial Transplant. 1999;14(suppl_4):5–6.CrossRefPubMedGoogle Scholar
  43. 43.
    Raz I, Wilson PW, Strojek K, Kowalska I, Bozikov V, Gitt AK, et al. Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care. 2009;32(3):381–6.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Toyoda M, Kimura M, Yamamoto N, Miyauchi M, Umezono T, Suzuki D. Insulin glargine improves glycemic control and quality of life in type 2 diabetic patients on hemodialysis. J Nephrol. 2012;25(6):989–95.CrossRefPubMedGoogle Scholar
  45. 45.
    Bouchi R, Babazono T, Onuki T, Mitamura K, Ishikawa Y, Uchigata Y, et al. Administration of insulin glargine thrice weekly by medical staff at a dialysis unit: a new insulin regimen for diabetic management in physically impaired patients undergoing hemodialysis. Diabetol Int. 2011;2(4):197–201.CrossRefGoogle Scholar
  46. 46.
    Kiss I, Arold G, Roepstorff C, Bøttcher SG, Klim S, Haahr H. Insulin degludec: pharmacokinetics in patients with renal impairment. Clin Pharmacokinet. 2014;53(2):175–83.CrossRefPubMedGoogle Scholar
  47. 47.
    Jacobsen LV, Popescu G, Plum A. Pharmacokinetics of insulin detemir in subjects with renal or hepatic impairment. Diabetes. 2002;51:A102.Google Scholar
  48. 48.
    Holmes G, Galitz L, Hu P, Lyness W. Pharmacokinetics of insulin aspart in obesity, renal impairment, or hepatic impairment. Br J Clin Pharmacol. 2005;60(5):469–76.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Jackson M, Holland M, Nicholas J, Lodwick R, Forster D, Macdonald I. Hemodialysis-induced hypoglycemia in diabetic patients. Clin Nephrol. 2000;54(1):30–4.PubMedGoogle Scholar
  50. 50.
    Burmeister JE, Scapini A, da Rosa MD, da Costa MG, Campos BM. Glucose-added dialysis fluid prevents asymptomatic hypoglycaemia in regular haemodialysis. Nephrol Dial Transplant. 2007;22(4):1184–9.CrossRefPubMedGoogle Scholar
  51. 51.
    Raimann JG, Kruse A, Thijssen S, Kuntsevich V, Dabel P, Bachar M, et al. Metabolic effects of dialyzate glucose in chronic hemodialysis: results from a prospective, randomized crossover trial. Nephrol Dial Transplant. 2011;27(4):1559–68.CrossRefPubMedGoogle Scholar
  52. 52.
    Almalki MH, Mansour AM, Almehthel MS, Sirrs SM. Subcutaneous versus intraperitoneal insulin for patients with diabetes mellitus on continuous ambulatory peritoneal dialysis: meta-analysis of non-randomized clinical trials. Clin Invest Med (Online). 2012;35(3):E132.CrossRefGoogle Scholar
  53. 53.
    Quellhorst E. Insulin therapy during peritoneal dialysis: pros and cons of various forms of administration. J Am Soc Nephrol. 2002;13(suppl 1):S92–S6.PubMedGoogle Scholar
  54. 54.
    Umpierrez GE, Gianchandani R, Smiley D, Jacobs S, Wesorick DH, Newton C, et al. Safety and efficacy of sitagliptin therapy for the inpatient management of general medicine and surgery patients with type 2 diabetes: a pilot, randomized, controlled study. Diabetes Care. 2013;36(11):3430–5.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    • Pasquel FJ, Gianchandani R, Rubin DJ, Dungan KM, Anzola I, Gomez PC, et al. Efficacy of sitagliptin for the hospital management of general medicine and surgery patients with type 2 diabetes (Sita-Hospital): a multicentre, prospective, open-label, non-inferiority randomised trial. Lancet Diabetes Endocrinol. 2017;5(2):125–33. The use of DPP-IV inhibitors in hospitalized patients is a new paradigm to offer easy and effective therapy in the hospital with low risk for hypoglycemia. This study specifically explores the use of sitagliptin. CrossRefPubMedGoogle Scholar
  56. 56.
    • Garg R, Schuman B, Hurwitz S, Metzger C, Bhandari S. Safety and efficacy of saxagliptin for glycemic control in non-critically ill hospitalized patients. BMJ Open Diabetes Res Care. 2017;5(1):e000394. Another exploration into DPP-IV inhibitors, specifically saxaglipitin, as non-inferior to certain diabetes regimens with low risk for hypoglycemia. CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    • Vellanki P, Alexanian S, Baldwin D, Rasouli N, Anzola IA, Ramos C, et al. Editors. Efficacy and safety of linagliptin in general surgical patients with type 2 diabetes: linagliptin surgery trial. Diabetes; 2017: American Diabetes Association 1701 N Beauregard St, Alexandria, Va 22311–1717 USA. Demonstration of linagliptin as an effective treatment for mild-to-moderate hyperglycemia with lower incidence of hypoglycemia than basal/bolus regimens. Google Scholar
  58. 58.
    • Umpierrez GE, Cardona S, Chachkhiani D, Fayfman M, Saiyed S, Wang H, et al. A randomized controlled study comparing a DPP4 inhibitor (linagliptin) and basal insulin (glargine) in patients with type 2 diabetes in long-term care and skilled nursing facilities: linagliptin-LTC trial. J Am Med Dir Assoc. 2017; Incorporating the DPP-IV inhibitor linagliptin as part of diabetes regimens on discharge to nursing homes is particulalry safe with lower incidences of hypoglycemia in this at-risk population. Google Scholar
  59. 59.
    Meier JJ, Weyhe D, Michaely M, Senkal M, Zumtobel V, Nauck MA, et al. Intravenous glucagon-like peptide 1 normalizes blood glucose after major surgery in patients with type 2 diabetes. Crit Care Med. 2004;32(3):848–51.CrossRefPubMedGoogle Scholar
  60. 60.
    Galiatsatos P, Gibson BR, Rabiee A, Carlson O, Egan JM, Shannon RP, et al. The glucoregulatory benefits of glucagon-like peptide-1 (7-36) amide infusion during intensive insulin therapy in critically ill surgical patients: a pilot study. Crit Care Med. 2014;42(3):638–45.CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    • Davies MJ, Bain SC, Atkin SL, Rossing P, Scott D, Shamkhalova MS, et al. Efficacy and safety of liraglutide versus placebo as add-on to glucose-lowering therapy in patients with type 2 diabetes and moderate renal impairment (LIRA-RENAL): a randomized clinical trial. Diabetes Care. 2016;39(2):222–30. Patients with mild-to-moderate renal impairment can still obtain benefits of the GLP-1 agonist liraglutide without further compromise to renal function. PubMedGoogle Scholar
  62. 62.
    • Lalau J-D, Kajbaf F, Bennis Y, Hurtel-Lemaire A-S, Belpaire F, De Broe ME. Metformin treatment in patients with type 2 diabetes and chronic kidney disease stages 3A, 3B, or 4. Diabetes Care. 2018; New data to suggest patients with moderate-to-servere renal impairment can still benefit from metformin in modified doses, without further compromising renal function or increasing the incidence of lactic acidosis. CrossRefPubMedGoogle Scholar
  63. 63.
    Metformin prescribing information. Bristol-Meyers Squibb. Available at June 2018.

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Ravi Iyengar
    • 1
  • Jennifer Franzese
    • 1
  • Roma Gianchandani
    • 1
    Email author
  1. 1.Department of Metabolism, Endocrinology, and Diabetes, Department of Internal MedicineUniversity of MichiganAnn ArborUSA

Personalised recommendations